Niclosamide Mitochondrial Uncoupling for IBD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease are limited by toxicity, cost, and convenience, with existing therapies often having severe side effects and limited efficacy, and there is a need for more effective and safer alternatives.
Innovation Solution
The use of niclosamide, a mitochondrial uncoupling agent with a good safety profile, which selectively targets and kills pathogenic T cells associated with IBD by disrupting their mitochondrial energy cycle, allowing for local administration to minimize systemic toxicity and combine with other therapeutic regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TNF-alpha drugs are used to treat IBD, then clinical efficacy is improved, but severe systemic side effects occur
Solution Approach 1:
The patent applies local quality by developing formulations that target specific tissues (intestinal mucosa) rather than distributing the drug systemically throughout the body. This localized delivery maintains high efficacy at the disease site while minimizing exposure and harmful effects in other organs, directly addressing the contradiction between clinical efficacy and systemic side effects
Solution Approach 2:
The patent uses an intermediary delivery system (such as carrier molecules or targeted vehicles) to transport the therapeutic agent specifically to the intestinal mucosa. This intermediary mechanism enables precise delivery to the target tissue, achieving effective treatment while preventing systemic distribution and associated toxicities
2Reliability
If corticosteroids are used to treat moderate to severe IBD, then clinical remission is achieved, but serious side effects occur with long-term use
Solution Approach 1:
The patent employs a short-acting, locally-targeted therapeutic agent that provides effective treatment during its brief presence at the disease site, then naturally clears from the system. This approach achieves clinical remission without the need for prolonged use, thereby avoiding the accumulation of serious side effects associated with long-term corticosteroid therapy
Solution Approach 2:
The patent extracts the essential therapeutic activity from systemically-acting drugs and concentrates it into a locally-delivered formulation. By taking out the active ingredient and delivering it precisely where needed, the treatment achieves remission while eliminating the harmful systemic effects of traditional corticosteroids
3Reliability
If immunosuppressive drugs are used to treat moderate to severe IBD, then symptom control is attempted, but numerous contraindications and severe side effects occur
Solution Approach 1:
The patent applies local quality by confining the immunosuppressive activity to the intestinal mucosa through targeted delivery mechanisms. This localized action provides symptom control at the disease site while preventing systemic immunosuppression and its associated contraindications and side effects
Solution Approach 2:
The patent segments the therapeutic effect by delivering the immunosuppressive agent through multiple targeted pathways (e.g., oral, rectal, or intraluminal delivery) that confine the drug to the gastrointestinal tract. This segmentation of delivery routes ensures symptom control without systemic absorption, thereby reducing contraindications and side effects
4Adaptability or versatility
If systemic administration of therapeutic drugs is used, then broad coverage is achieved, but increased systemic toxicity occurs
Solution Approach 1:
The patent applies local quality by designing delivery systems that provide broad coverage within the gastrointestinal tract while maintaining specificity to the intestinal mucosa. This localized broad coverage achieves treatment of various IBD conditions without distributing the drug systemically, thereby avoiding increased toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Niclosamide effectively induces cell death in pathogenic T cells, providing a highly efficient and safer treatment option for IBD with reduced systemic toxicity and cost, suitable for diverse patient populations and resistant cases, including those nonresponsive to anti-TNF-alpha therapy.
Implementation Method 1
niclosamide, a mitochondrial uncoupling agent with a good safety profile, which selectively targets and kills pathogenic T cells associated with IBD by disrupting their mitochondrial energy cycle
Data Source
AI summary
This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.